Literature DB >> 22953238

The Prevalence of Juvenile Huntington's Disease: A Review of the Literature and Meta-Analysis.

Oliver Quarrell, Kirsty L O'Donovan, Oliver Bandmann, Mark Strong.   

Abstract

Juvenile Huntington's disease (JHD) is usually defined as Huntington's disease with an onset ≤ 20 years. The proportion of JHD cases reported in studies of Huntington's disease (HD) varies. A review of the literature found 62 studies that reported the proportion of JHD cases amongst all HD cases. The proportion of JHD cases in these studies ranged from 1% to 15%, and in a meta-analysis the pooled proportion of JHD cases was 4.92% (95% confidence interval of 4.07% to 5.84%). Limiting the analysis to the 25 studies which used multiple methods of ascertainment resulted in a similar pooled proportion of 5.32%, (95% confidence interval 4.18% to 6.60%). A small difference was observed when the meta-analysis was restricted to studies from countries defined by the World Bank as high income, that used multiple methods of ascertainment, and that were conducted since 1980 (4.81%, 95% confidence interval 3.31% to 6.58%, n=11). This contrasts with the pooled result from three post 1980 studies using multiple methods of ascertainment from South Africa and Venezuela, defined by the World Bank as upper middle income, where the estimated mean proportion was 9.95%, (95% confidence interval 6.37% to 14.22%). These results, which are expected to be more robust than those from a single study alone, may be helpful in estimating the proportion of JHD cases in a given population. Key Words: Juvenile Huntington's disease, prevalence, epidemiology.

Entities:  

Year:  2012        PMID: 22953238      PMCID: PMC3426104          DOI: 10.1371/4f8606b742ef3

Source DB:  PubMed          Journal:  PLoS Curr        ISSN: 2157-3999


Introduction

Huntington’s disease (HD) is an autosomal dominant, neurodegenerative disorder with onset usually, but not exclusively, between 35 and 50 years of age1 . Onset ? the age of 20 is classified as juvenile onset Huntington’s disease (JHD), which can be further divided into childhood (0-10 years) and adolescent (11-20 years) onset. Although there are many similarities with the adult form of the disease, JHD has a clinically distinct presentation; the dominant motor feature being a parkinsonian type syndrome of rigidity, dystonia and bradykinesia, rather than chorea2, 3, 4 . In addition, childhood cases may also present with cerebellar signs, epilepsy, myoclonus and spasticity5, 6 . Behavioural problems and cognitive decline are also common in JHD4, 6 , with additional features of developmental delay and autism in childhood cases5 . The causative mutation in HD has been identified as an expanded CAG repeat sequence in the first exon of the HTT gene 7 . A CAG repeat of ? 40 is unequivocally fully penetrant, with CAG repeats of 36-39 showing reduced penetrance8 . JHD is usually associated with a CAG repeat of ? 60 repeats in approximately 50% of cases9 , with childhood onset often exhibiting a repeat size of ? 805, 10 . However, consistent with findings in adult cases,CAG repeat size does not always correlate with age of onset in JHD5 . The prevalence of HD is considered to be approximately 4-10 cases per 100,000 in Caucasian populations 11, 12, 13, 14 but this may be higher15 . Such variability may be accounted for in part by differences in methods of ascertainment, prevalence method used (period or point prevalence) and diagnostic/age of onset criteria. Low prevalence rates of less than 1 case per 100,000 have been reported in Japanese populations11, 12 . Well developed medical services in Japan mean under-ascertainment is unlikely12 .. More recently, Warby et al (2011)16 have summarised prevalence data from around the world and discussed the reasons for low prevalence in some countries. Prevalence in African and American black populations is also considered to be lower than in white populations17, 18 . However this may represent under-ascertainment12 , with studies employing more extensive methods reporting equivalent rates19 . Juvenile onset HD is considered to be extremely rare, with few clinicians ever seeing more than one case. In 1981, Hayden summarised the prevalence of JHD, expressed as a percentage of the total number of HD cases surveyed11 . Presented by country, a mean of 5.7% of HD cases were found to be of juvenile onset, with a range of 1-9.6%. Childhood onset was rarer than adolescent onset, with means of 1.3% and 4.4%, respectively. These findings are consistent with the widely accepted belief that JHD is indeed a rare form of the disease. Although Hayden’s work has been the first and only summary of the epidemiology of JHD known to the authors, there are several limitations in combining and interpreting the data in this way to obtain an estimate of the proportion of JHD cases. The first concerns the pooling of data from different types of studies, such as those reporting period with those reporting point prevalence. Secondly, data are included that are published in more than one paper. Furthermore, the Hayden report includes studies which, due to differences in country and year of study, report prevalence in populations with different age-sex structures. This potentially introduces a bias; lower life expectancies artificially raise the proportion of cases with juvenile onset as patients with adult onset are more likely to die prematurely from unrelated causes. The aim of the current study is therefore to update and expand Hayden’s work, exploring the impact of study level factors on the estimated proportion of HD cases with juvenile onset.

Methods

We searched the MEDLINE and EMBASE databases for the period 1981-May 2011. The following search terms were used in the title and abstract field: Huntington’s AND disease AND Prevalence Huntington’s AND disease AND Population Huntington’s AND disease AND Epidemiology* Huntington’s AND disease AND Incidence Huntington*AND Prevalence Huntington*AND Population Huntington*AND Epidemiology* Huntington*AND Incidence Juvenile AND Huntington* (* indicates searches including unlimited truncations of the target word) Studies that did not include a defined HD population were excluded. Literature reviews were included if they provided information on the total number of HD cases surveyed. Studies were excluded if they did not include information on ages of onset, number of juvenile cases, or patients with onset before age 21. We only used published data once. Articles not written in English were excluded, the one exception being the German language Panse study20 as it was included in the original Hayden study. For each study, data relating to the total number of HD cases and total number of juvenile cases were extracted. In addition, the number of cases with childhood (onset 0-10 years) and adolescent (11-20 years) was extracted if available. For each study the proportion of HD cases with juvenile onset was calculated and expressed as a percentage. Sub-group analyses. Studies were subdivided based on methodology, year of publication and country studied. Study methodology was defined as either “multiple methods of ascertainment” or “HD roster/clinic population”. Of these, the most accurate estimates of prevalence were considered to be from studies with multiple methods of ascertainment. Therefore, studies meeting this criterion were used for all further sub-analyses. To account for any biases relating to age-based population structure, studies were further divided by economic status as defined by the World Bank21 . To account for any time related changes in population structure and to gain an accurate estimate of the current prevalence of JHD, the final sub-group analysis was conducted using studies published between 1980 and 2011. Statistical analysis. Within each sub-group, study results were pooled in a meta-analysis. Proportions were first transformed using the Freeman-Tukey double arc-sin transformation before being combined. A random effects model was assumed for each meta analysis due to the heterogeneity in the study characteristics. For each meta-analysis the I2 value is reported as a measure of statistical heterogeneity. Confidence intervals presented for each individual study were computed using the exact binomial method. All analyses were conducted using the “meta” package in R 2.13.1 22 .

Results

The search criteria produced a total of 1594 articles. Of these, 48 studies met the inclusion criteria. These studies were combined with those reported by Hayden11 , increasing the total number of studies to 59. The study by van Dijk et al 2 was excluded as this literature survey was specifically searching for articles with JHD cases and did not define a denominator total HD population. Although the aim of the study was to update Hayden's work we also included the paper by Julia Bell 1948 23 . The pooled data presented in the Cameron and Venters paper24 , which originally included data from their own sample (Scotland) plus that of Bickford and Ellison (Cornwall)25and Pleydell (Northamptonshire)26, 27 , has been disaggregated to recreate counts in the three study populations. No JHD cases were reported in the Bickford and Ellison paper25 and this was therefore excluded. Therefore, only the data from Pleydell26, 27 and Cameron and Venters24 are included in our review. Although the counts of JHD cases in the Cameron and Venters paper are not explicitly reported, these were deduced by calculating the number of cases reported in the two Pleydell26, 27studies. Cases in the Hayden South African study28were categorised by ethnicity into white, mixed and black populations recognising that the white South African population has a mortality distribution similar to that in countries listed as high income, whereas the mixed population has a mortality distribution similar to countries in the upper middle income group (no cases were reported in the black population). To avoid double counting of data in the meta-analysis, the overall total for South Africa was not included. This produced a revised total of 62 studies. A summary of these studies is presented in an appendix. The results of the meta-analysis are presented as a forest plot in Figure 1. The black population data from Hayden28 were excluded for purposes of the statistical analysis since there were no HD cases reported. The overall pooled proportion of JHD cases was 4.92% (95% confidence interval (CI) 4.07% to 5.84%), with a range of 1-15%. Sub-analyses. Table 1 below summarises the results of a number of sub-group analyses of the data which are described below. HD roster or clinic. Thirty-five studies reported data obtained from either a HD roster or clinic population which are summarised in Fig 2. It is possible that a centre which uses a roster approach may have some patients included in different studies but our final analysis was based on studies which used multiple methods of ascertainment (MMA) so this is is less likely to be a problem. Multiple methods of ascertainment (MMA). There were 25 studies applying MMA summarised in Fig 3. Income status. The World Bank21 classification of countries was used to subdivide the studies, the majority (22 studies) came from the high income group. By comparison, three studies came from the upper middle income group, two came from Venezuela10, 44 and the third study was that of Hayden28, where the data from the White South African population was included in the high income analysis and data from the mixed population was included in the middle income group. Fig 4 summarises these studies from high income countries. Post 1980 studies. Of the MMA studies, 14 were published between 1980 and 2011. Ten were conducted in high income and three in the upper middle income. As above, the final study was that of Hayden28, where the data from the white South African population was included in the high income analysis and data from the mixed population was included in the upper middle income group. The forest plot for studies from high income countries is shown in Fig 5 and the forest plot for studies from upper middle income countries is shown as Fig 6. Summary of Meta-Analyses Data on childhood and adolescent onset cases was available for 42 studies, representing 475 cases. Of these, 111 (23.4%) and 364 (76.6%) were childhood and adolescent onset, respectively. Only seven studies found a higher proportion of childhood onset cases, with two studies reporting equal numbers. Therefore in 76% of studies, adolescent onset occurred more frequently than childhood onset. When we consider just the most recent studies of the highest quality from the high income group (the MMA-post 1980 studies), the pattern is similar with 40 out of 50 (80%) cases being of adolescent onset.

Discussion

Main results. In the meta-analysis of all the studies identified in this review we estimate the proportion of JHD cases to be 4.92% (95% CI 4.07% - 5.84%). In order to expand on Hayden’s original work11 and produce more robust estimates of the proportion of JHD cases, the potential sources of bias associated with the various studies were considered. We identified 35 studies which were based on clinic lists or rosters (Figure 2); and 25 studies which used multiple methods of ascertainment (Figure 3). These gave mean estimates of the proportion of 4.94% and 5.32% respectively. A clinic list or roster approach may downwardly bias the proportion of JHD cases if it is perceived that the clinic serves mainly adult patients. Studies with multiple methods of ascertainment are more likely to give a robust estimate. Most studies were conducted in Europe and North America so the effect of considering geography was minimal (Figure 4); however, the three studies from economically less developed countries (Figure 5) were effectively from the South African black population and Venezuela. The longitudinal study of families from the area around Lake Maricaibo has been important in that it contributed to the original localisation of the gene to chromosome 4 and for an understanding of the natural history of the condition 10 44 80 The mean proportion of JHD cases from these three studies was 9.95% (95% CI 6.57% - 14.22%). If the age of death was lower in the general population in which these cases live, then those with HD who were destined to develop the condition later in life may not manifest as they die of other causes; consequently the proportion of JHD cases will be higher. In addition, the patients with HD living around Lake Maricaibo are a relatively closed community so it is possible that this also has an effect on the proportion of JHD cases. These three studies were reported after 1980. Eleven studies were reported after 1980, which used multiple methods of ascertainment, and were from economically more developed countries; these gave a slightly lower proportion of 4.81% (95% CI 3.31% – 6.58%) and may be considered the most robust estimate to use when considering European and North American populations. Implications for Research. At present, there is no treatment to alter the natural history of HD. As soon as treatments become available which do alter the natural history of HD, then it will be important to assess their effects on patients at the more extreme end of the phenotypic spectrum. If a faster rate of disease progression can be demonstrated in this group of patients, then any compound which affects the natural history of HD may show an effect more quickly. In June 2010, the UK population was estimated to be 62.3 million79 . If we assume the prevalence of HD is approximately 4-10 per 10011 12 13 14 , in the UK and we also assume some degree of under-ascertainment; therefore, using a figure of 100 HD patients per million would imply that there are around 6,230 patients with HD in the UK, so we should expect to see approximately 300 cases with an onset under the age of 20 years (95% CI 205 – 411). Identifying these patients represents a considerable challenge. Conclusion We have presented a review of the proportion of cases with JHD from 62 studies. Using data from 25 studies after 1980 which were mainly fromNorthern Europe suggests that the mean proportion of JHD cases is just less than 5%.
Table 1

Summary of Meta-Analyses

Study typenumberMean %95%ConfidenceIntervalRange%
All studies624.924.07-5.841-15
HD clinic/Roster354.943.85-6.161-15
Multiple Metods of AscertainmentMMA255.324.18-6.601-15
MMA + High Income224.703.71-5.801-12
MMA + UpperMiddle Income39.956.37-14.226-15
MMA + Post 1980 +High Income114.813.31-6.581-10
MMA + Post 1980 +Upper Middle Income39.956.37- 14.226-15
Summary of all studies used in this analysis

* refers to studies included in the original Hayden study11  The paper from Pleydell 195426 was included with additional data from Pleydell 195527    - means there was no furher specification of age

    0 - 10 years 11-20 years Total JHD 
AuthorsPublicationyearLocationTotal HD casesNumber%Number%Number%
*Davenport & Muncey29 1916USA13832.221.453.6
*Spillane &Phillips30  1937 South Wales 21 0 0 2 9.5 2 9.5
 *Panse20  1942Germany  446 71.6  17 3.8 24 5.4
 Pleydell26  1954 England 17 0 0 2 11.8 2 11.8
 *Reed et al18  1958 USA 203 0 0 12 5.9 12 5.9
*Brothers31  1964 Australia206  4 1.9 11 5.3 15 7.3
 *Cameron & Venters24  1967 Scotland 143 - - - - 3 21
 *Heathfield32  1967 England 81 0 0 2 2.5 2 2.5
*Oliver33 1970England11543.576.1119.6
 *Mattsson34  1974 Sweden 362 - - - - 174.7 
 *Stevens35  1976 England 133 0  1 0.8 1 0.8
 Walker et al36  1981 SouthWales 333 3 0.9 11 3.3 14 4.2
 *Hayden et al28  1982 S Africa Total 219 6 2.7 11 5 17 7.7
   S AfricaWhites 147 3 2.0 3 2.0 6 4.1
  S Africa Mixed 72 3 4.2 8 11.1 11 15.3
   S AfricaBlacks 0   0  0 
 Myers et al37  1982 USA 83 2 2.4 7 8.4 9 10.8
 Went et al38  1983 Netherlands 276 5 81. 3 1.1 8 2.9
 Di Maio et al39  1984 Italy 95 - - - - 4 4.2
 Went et al40  1984 Netherlands 1246 13 1.0 0 0 13 1.0
Farrer &Conneally41 1985USA56940.7244.2284.9
Hayden et al42 1985USA598----8914.9
 Groppi et al43  1986 Italy 48 - - - 5 10.4
 Young et al44 1986  Venezueala65  1 1.5 3 4.6 4 6.2
 Folstein et al19  1987 USA 217 - - - - 15 6.9
 Adams et al45  1988 USA 611 5 0.8 25 4.1 30 4.9
 Fromtali et al46  1990 Italy 299 2 0.7 9 3 11 3.7
 Pavomi et al47  1990 Italy 47 0 0 1 3.1 1 2.1
 Pridmore48  1990 Tasmania 48 0 0 3 6.3 3 6.3
 Roos et al49  1991 Netherlands 632 - - - 12 1.9
Leung et al50 1992China &Hong Kong8944.50044.5
 Ridley et al51  1992 USA 3945 - - - - 208 5.3
 Morrison &Nevin52  1993 N Ireland 12 0 0 1 8.3 1 8.3
 Roos et al53  1993 Netherlands 1106 - - - - 6.5 5.9
 Simpson et al54  1993 Scotland 82 0 0 3 3.7 3 3.7
 Watt & Seller55  1993 England 101 - - - - 4 4.0
 Shiwach56  1994 England 135 0 0 8 5.9 8 5.9
 Morrison et al57  1995 N Ireland 101 2 2 4 4 6 6
Sanchest et al59 1996Spain3100412.9412.9
 Alonso et al58  1997 Mexico 83 - - - - 6 7.2
 Siesling et al4  1997 Netherlands 2787 - - - - 65 2.3
Gomez-Totosa et al59 1998Spain8111.267.478.6
 Atac et al60  1999 Turkey 27 0 2 7.4 2 7.4
 Faroud et al61  1999 USA 2068 - - - - 94 4.5
 Louis et al62  1999USA  43 0 0 1 2.3 1 2.3
 Lima et al63  2000 Brazil 30 0 0 3 10 3 10
 Raskin et al64  2000Brazil  59 35.1  4 6.8 7 11.9
 Rasmussen et al65  2000 Mexico 364 7 1.9 18 4.9 25 6.9
 Almqvist et al66  2001 Canada 102 0 0 2 2 2 2.0
Murgod et al67 2001India26----415.4
Maat Kievit et al68 2002Netherlands755----183.0
Akbas Erginel-Unaltuna69   2003 Turkey 127 1 0.8 7 5.5 86.3 
 Creighton et al70  2003 Canada 282 - - - - 51.8 
 do Como Costaet al71  2003 Portugaul 120 3 2.5 1 0.8 4 3.3
Cannella et al72 2004Italy52451529.95710.9
 Wexler et al10  2004 Venezueala 443 - - - - 40 9.0
 Ramos-Aroyo et al73  2005 Spain 112 - - - 7 6.3
Ruocco et al74 2006Brazil50242448.0
 Ribai et al6  2007 France 1453 8 0.6 21 1.4 29 2.0
Zidovska et al75 2007Czech Republic411----122.9
 Van Duijn et al76  2008 Netherlands - - - - - 1 0.6
 Alonso et al77  2009 Mexico 691 16 2.3 41 5.9 57 8.2
 Torres et al78 2010 Peru  131 - - - - 96.9 
  64 in total

1.  Huntington's disease out of the closet?

Authors:  Michael Rawlins
Journal:  Lancet       Date:  2010-06-30       Impact factor: 79.321

2.  Differences in duration of Huntington's disease based on age at onset.

Authors:  T Foroud; J Gray; J Ivashina; P M Conneally
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-01       Impact factor: 10.154

3.  Some problems in Huntington's chorea.

Authors:  D Cameron; G A Venters
Journal:  Scott Med J       Date:  1967-04       Impact factor: 0.729

4.  Huntington's chorea. Investigation into the prevalence of this disease in the area covered by the North East Metropolitan Regional Hospital Board.

Authors:  K W Heathfield
Journal:  Brain       Date:  1967-03       Impact factor: 13.501

5.  Epidemiologic approach to Huntington's disease in northern Italy (Ferrara area).

Authors:  M Pavoni; E Granieri; V Govoni; V Pavoni; L Del Senno; G Mapelli
Journal:  Neuroepidemiology       Date:  1990       Impact factor: 3.282

6.  Molecular diagnosis of Huntington disease in Portugal: implications for genetic counselling and clinical practice.

Authors:  Maria do Carmo Costa; Paula Magalhães; Fátima Ferreirinha; Laura Guimarães; Cristina Januário; Isabel Gaspar; Leal Loureiro; José Vale; Carolina Garrett; Fernando Regateiro; Marina Magalhães; Alda Sousa; Patrícia Maciel; Jorge Sequeiros
Journal:  Eur J Hum Genet       Date:  2003-11       Impact factor: 4.246

7.  Huntington's disease in Grampian region: correlation of the CAG repeat number and the age of onset of the disease.

Authors:  S A Simpson; M J Davidson; L H Barron
Journal:  J Med Genet       Date:  1993-12       Impact factor: 6.318

8.  Huntington disease in Georgia: age at onset.

Authors:  P Adams; A Falek; J Arnold
Journal:  Am J Hum Genet       Date:  1988-11       Impact factor: 11.025

9.  Dystonia in Huntington's disease: prevalence and clinical characteristics.

Authors:  E D Louis; P Lee; L Quinn; K Marder
Journal:  Mov Disord       Date:  1999-01       Impact factor: 10.338

10.  Juvenile Huntington disease.

Authors:  J G van Dijk; E A van der Velde; R A Roos; G W Bruyn
Journal:  Hum Genet       Date:  1986-07       Impact factor: 4.132

View more
  39 in total

Review 1.  Dopamine Receptors and Neurodegeneration.

Authors:  Claudia Rangel-Barajas; Israel Coronel; Benjamín Florán
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 2.  Genetics of hereditary neurological disorders in children.

Authors:  Yue Huang; Sui Yu; Zhanhe Wu; Beisha Tang
Journal:  Transl Pediatr       Date:  2014-04

3.  Comparison of mid-age-onset and late-onset Huntington's disease in Finnish patients.

Authors:  Jussi O T Sipilä; Tommi Kauko; Markku Päivärinta; Kari Majamaa
Journal:  J Neurol       Date:  2017-08-28       Impact factor: 4.849

4.  Managing juvenile Huntington's disease.

Authors:  Oliver W J Quarrell; Martha A Nance; Peggy Nopoulos; Jane S Paulsen; Jonathan A Smith; Ferdinando Squitieri
Journal:  Neurodegener Dis Manag       Date:  2013-06-01

Review 5.  Therapeutic effects of stem cells in rodent models of Huntington's disease: Review and electrophysiological findings.

Authors:  Sandra M Holley; Talia Kamdjou; Jack C Reidling; Brian Fury; Dane Coleal-Bergum; Gerhard Bauer; Leslie M Thompson; Michael S Levine; Carlos Cepeda
Journal:  CNS Neurosci Ther       Date:  2018-03-06       Impact factor: 5.243

6.  Neuropathological Comparison of Adult Onset and Juvenile Huntington's Disease with Cerebellar Atrophy: A Report of a Father and Son.

Authors:  Caitlin S Latimer; Margaret E Flanagan; Patrick J Cimino; Suman Jayadev; Marie Davis; Zachary S Hoffer; Thomas J Montine; Luis F Gonzalez-Cuyar; Thomas D Bird; C Dirk Keene
Journal:  J Huntingtons Dis       Date:  2017

7.  The Changing Age of Individuals Seeking Presymptomatic Genetic Testing for Huntington Disease.

Authors:  Melissa A Holman; John Quillin; Timothy P York; Claudia M Testa; Ami R Rosen; Virginia W Norris
Journal:  J Genet Couns       Date:  2018-02-20       Impact factor: 2.537

Review 8.  Juvenile Huntington's Disease: Diagnostic and Treatment Considerations for the Psychiatrist.

Authors:  Joanna Quigley
Journal:  Curr Psychiatry Rep       Date:  2017-02       Impact factor: 5.285

9.  Pallidal deep brain stimulation in juvenile Huntington's disease: local field potential oscillations and clinical data.

Authors:  Stefano Ferrea; Stefan J Groiss; Saskia Elben; Christian J Hartmann; Steve B Dunnett; Anne Rosser; Carsten Saft; Alfons Schnitzler; Jan Vesper; Lars Wojtecki
Journal:  J Neurol       Date:  2018-05-03       Impact factor: 4.849

10.  The personal experience of parenting a child with juvenile Huntington's disease: perceptions across Europe.

Authors:  Virginia Eatough; Helen Santini; Christine Eiser; Marie-Louise Goller; Wioletta Krysa; 'Annunziata' de Nicola; Matteo Paduanello; Martina Petrollini; Maria Rakowicz; Ferdinando Squitieri; Aad Tibben; Katie Lee Weille; Bernhard Landwehrmeyer; Oliver Quarrell; Jonathan A Smith
Journal:  Eur J Hum Genet       Date:  2013-02-27       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.